At last check in after-hours trading, shares of Neuronetics Inc. (Nasdaq: STIM) were up 12.73% at $3.10 in absence of any major news. STIM stock closed the last session at $2.75 trading between $2.62 and $2.80.
What STIM has gone through?
The TrakStar platform has just been enhanced by Neuronetics (STIM), providing all NeuroStar clinicians with a more seamless patient management experience. The third TrakStar improvement in 2022, this release demonstrates Neuronetics’ dedication to innovation.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
- To make its TrakStar platform a more intelligent and effective tool, Neuronetics continued to innovate. The most recent enhancements make it simpler to identify new patients and those in need of repeat treatment by connecting its proprietary PHQ-10 platform with our HIPAA-compliant TrakStar patient data management system.
- STIM loves its NeuroStar providers and the crucial job they carry out to assist those with drug-resistant depression, therefore the company thinks it’s necessary to give them the finest and most modern resources to locate and assist those in need more rapidly.
- The TrakStar enhancements also offer a streamlined user interface that makes it simple to swiftly filter and rank potential patients. Launched in early 2022, NeuroStar’s proprietary PHQ-10 tool creates fresh patient candidates that are immediately imported into TrakStar.
The benefits investigation (BI) results are instantly shown in TrakStar and may be transformed into a NeuroStar patient with a single click. Other TrakStar improvements include a redesigned tutorial page, updated reporting that highlights patients who have not finished prescribed treatment or who may require re-treatment, and new clinical outcomes scores that can be automatically emailed to patients using templates that can be customized.
What makes STIM unique?
By giving therapists the most cutting-edge tools to accomplish their jobs most effectively and efficiently, NeuroStar offers an exceptional degree of assistance. These recent TrakStar updates strengthen STIM’s lead management capabilities by automating and streamlining the patient identification and conversion process. As a result, Neuronetics (STIM) is able to assist more individuals with neurohealth problems like depression.
